Dicerna expects to continue collaborating with Novo's rivals after potential acquisition

CEO at Dicerna Douglas Fambrough is fully anticipating that the US-based biotech company will live up to the obligations it has made to other companies, even in the case that the recently announced takeover bid by Novo Nordisk is a success, he tells MedWatch.

Photo: Mike Blake/Reuters/Ritzau Scanpix

Even if Novo Nordisk's takeover bid becomes a success, business will continue as usual when it comes to Dicerna's partnerships with Novo's rivals Eli Lilly and Boehringer Ingelheim, CEO at Dicerna Douglas Fambrough tells MedWatch.

This is at least what the CEO is expecting to happen.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs